Conference
A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers.
Authors
Liu J; Ray-Coquard IL; Selle F; Poveda A; Cibula D; Hirte HW; Raspagliesi F; Gladieff L; Harter P; Schiavetto I
Volume
32
Pagination
pp. 5519-5519
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2014
DOI
10.1200/jco.2014.32.15_suppl.5519
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X